167 related articles for article (PubMed ID: 26289868)
21. [Can physicians really save still more in drug prescriptions?].
Schmidt K
MMW Fortschr Med; 2006 Feb; 148(5):44-5. PubMed ID: 16518938
[No Abstract] [Full Text] [Related]
22. [Pioglitazone in evaluation by IQWiG (Institute for Quality and Cost Effectiveness in Public Health)--tunnel vision instead of broad view].
MMW Fortschr Med; 2008 Aug; 150(32-35):56-7. PubMed ID: 19009700
[No Abstract] [Full Text] [Related]
23. [Economics under scrutiny - experts discuss long acting insulin analogs].
Pflege Z; 2011 Jan; 64(1):58. PubMed ID: 21305792
[No Abstract] [Full Text] [Related]
24. [Direct purchase of expensive medicine from the manufacturer may be required].
Zimmermann GW
MMW Fortschr Med; 2015 Jun; 157(11):12. PubMed ID: 26049324
[No Abstract] [Full Text] [Related]
25. [The new drug cost saving package. Sensible measures or risk for patients?].
Krankenpfl J; 2002; 40(5-6):159. PubMed ID: 12271499
[No Abstract] [Full Text] [Related]
26. Changes to the Pharmaceutical Benefits Advisory Committee.
Henry DA; Birkett DJ
Med J Aust; 2001 Mar; 174(5):209-10. PubMed ID: 11280687
[No Abstract] [Full Text] [Related]
27. [2009 laboratory reform--what needs consideration].
Zimmermann GW
MMW Fortschr Med; 2008 Sep; 150(36-37):8-9. PubMed ID: 18986112
[No Abstract] [Full Text] [Related]
28. Effects of a price cut reform on the cost and utilization of antidiabetic drugs in Korea: a national health insurance database study.
Suh HS; Kim JA; Lee IH
BMC Health Serv Res; 2018 Jun; 18(1):429. PubMed ID: 29879966
[TBL] [Abstract][Full Text] [Related]
29. [New drugs must henceforth be better than the current standard. What remains for physician therapy autonomy?].
Schmidt K
MMW Fortschr Med; 2006 Dec; 148(49-50):61, 63. PubMed ID: 17619334
[No Abstract] [Full Text] [Related]
30. [New drug agreement stands. No more deductions starting next year].
Schmidt K
MMW Fortschr Med; 2007 Nov; 149(47):56-7. PubMed ID: 18069140
[No Abstract] [Full Text] [Related]
31. Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance.
Yang BM; Bae EY; Kim J
Health Aff (Millwood); 2008; 27(1):179-87. PubMed ID: 18180493
[TBL] [Abstract][Full Text] [Related]
32. [Radiology and the law. In ambulatory treatment may contrast media be obtained via the hospital pharmacy?].
Frehse M; Kleinke S;
Rofo; 2003 May; 175(5):711-2. PubMed ID: 12816077
[No Abstract] [Full Text] [Related]
33. [Costs involved in the early and late phases of diabetes mellitus].
Liebl A
Internist (Berl); 2007 Jul; 48(7):708-14. PubMed ID: 17576527
[TBL] [Abstract][Full Text] [Related]
34. [The physician caught between two chairs. Comments on the difficulty in dealing with off-label use].
Harder Yv
Urologe A; 2007 Oct; 46(10):1429-34. PubMed ID: 17786403
[No Abstract] [Full Text] [Related]
35. [Expert consultant emphasizes more competition in health care].
Herz; 2003 Mar; 28(2):169-70. PubMed ID: 12722706
[No Abstract] [Full Text] [Related]
36. [Off-label use in psychopharmacotherapy].
Fritze J; Schmauss M
Nervenarzt; 2002 Aug; 73(8):796-9. PubMed ID: 12242971
[No Abstract] [Full Text] [Related]
37. [Obesity and diabetes mellitus: increasing problems call for increasing efforts].
Nauck M
Dtsch Med Wochenschr; 2010 May; 135(18):901. PubMed ID: 20425673
[No Abstract] [Full Text] [Related]
38. [Bonus-penalty regulation. What is coming for us?].
Stoschek J
MMW Fortschr Med; 2006 Nov; 148(44):56-7. PubMed ID: 17619442
[No Abstract] [Full Text] [Related]
39. [Health care reform: cutting back on surplus in the system].
Rüggeberg JA
Chirurg; 2006 Jul; Suppl():218. PubMed ID: 17855871
[No Abstract] [Full Text] [Related]
40. Post-marketing observational trials and catastrophic health expenditure.
Yudkin JS
BMJ; 2012 Jun; 344():e3987. PubMed ID: 22692653
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
